The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing

Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 1.2014

(2017) Mary B. Daly et al.   Journal of the National Comprehensive Cancer Network

Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening†

(2016) S. Paluch-Shimon et al.   ANNALS OF ONCOLOGY

Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations

(2016) Lu Yao et al.   BREAST CANCER RESEARCH AND TREATMENT

Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer

(2016) Juan Zhang et al.   BREAST CANCER RESEARCH AND TREATMENT

Prevalence ofBRCA1/2germline mutations in 21 401 families with breast and ovarian cancer

(2016) Karin Kast et al.   JOURNAL OF MEDICAL GENETICS

Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer

(2015) Michelle W. Wong-Brown et al.   BREAST CANCER RESEARCH AND TREATMENT

Population-Wide Screening for Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing?

(2015) Matthew B. Yurgelun et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive spectrum ofBRCA1andBRCA2deleterious mutations in breast cancer in Asian countries

(2015) Ava Kwong et al.   JOURNAL OF MEDICAL GENETICS

Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial

(2015) Xi-Chun Hu et al.   LANCET ONCOLOGY

Identification of a Comprehensive Spectrum of Genetic Factors for Hereditary Breast Cancer in a Chinese Population by Next-Generation Sequencing

(2015) Xiaochen Yang et al.   PLoS One

The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer

(2015) Ava Kwong et al.   Cancer Genetics

Worse Breast Cancer Prognosis of BRCA1/BRCA2 Mutation Carriers: What's the Evidence? A Systematic Review with Meta-Analysis

(2015) Alexandra J. van den Broek et al.   PLoS One

Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer

(2014) C. Wang et al.   ANNALS OF ONCOLOGY

Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis

(2014) Q. Zhong et al.   CLINICAL CANCER RESEARCH

Is it time for BRCA1/2 mutation screening in the general adult population?: impact of population characteristics

(2014) Glenn E. Palomaki   GENETICS IN MEDICINE

Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort

(2013) Rachel Greenup et al.   ANNALS OF SURGICAL ONCOLOGY

Prevalence ofBRCA1andBRCA2Germline Mutations in Breast Cancer Women of Multiple Ethnic Region in Northwest China

(2013) Jianghua Ou et al.   Journal of Breast Cancer

Clinical significance of large rearrangements inBRCA1andBRCA2

(2012) Thaddeus Judkins et al.   CANCER

Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

(2012) N. Mavaddat et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

NSGC Practice Guideline: Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian Cancer

(2012) Janice L. Berliner et al.   Journal of Genetic Counseling

Identification of BRCA1/2 Founder Mutations in Southern Chinese Breast Cancer Patients Using Gene Sequencing and High Resolution DNA Melting Analysis

(2012) Ava Kwong et al.   PLoS One

Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer

(2011) Juan Zhang et al.   BREAST CANCER RESEARCH AND TREATMENT

Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers

(2011) Larissa J. Lee et al.   CANCER

Breast Cancer Prognosis inBRCA1andBRCA2Mutation Carriers: An International Prospective Breast Cancer Family Registry Population-Based Cohort Study

(2011) Pamela J. Goodwin et al.   JOURNAL OF CLINICAL ONCOLOGY

Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer

(2010) Laura Cortesi et al.   BMC CANCER

BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasts and/or ovaries

(2010) D. G. Evans et al.   JOURNAL OF MEDICAL GENETICS

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

The role of BRCA mutation testing in determining breast cancer therapy

(2010) Alison H. Trainer et al.   Nature Reviews Clinical Oncology

BRCA1andBRCA2mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer

(2009) Michael J. Hall et al.   CANCER

Clinical and Pathologic Characteristics of Patients WithBRCA-Positive andBRCA-Negative Breast Cancer

(2008) Deann P. Atchley et al.   JOURNAL OF CLINICAL ONCOLOGY